Sachs, Mikkel Lindskov
Colding-Jørgensen, Morten
Helboe, Per
Sporrong, Sofia Kälvemark
Frøkjaer, Sven
Jelic, Katarina
Kaae, Susanne http://orcid.org/0000-0002-8187-365X
Funding for this research was provided by:
Novo Nordisk
Article History
First Online: 30 March 2019
Compliance with Ethical Standards
:
: Funding for this study was provided by Innovation Fund Denmark (Department of the Ministry of Higher Education and Science) and Novo Nordisk A/S as part of a public-industrial co-funded Ph.D. project. Publication of the study results was not dependent on the approval of either funder.
: Mikkel Lindskov Sachs was employed as a full-time industrial Ph.D. student at the University of Copenhagen and Novo Nordisk A/S during this study. Morten Colding-Jørgensen is a consultant and shareholder of Novo Nordisk A/S. Katarina Jelic is a full-time employee and shareholder of Novo Nordisk A/S. Per Helboe is a shareholder of multiple pharmaceutical companies, including Novo Nordisk A/S. Sven Frokjaer, Sofia Kälvemark Sporrong, and Susanne Kaae have no conflicts of interest that are directly relevant to the content of this article.
: The study and the related data management were approved by the Data Management Unit of the Faculty of Health and Medicines, University of Copenhagen. The Danish Data Protection Agency approved the study (Reference: SUND-2016-47).
: Participants were informed about the study and its aim and signed informed consent forms at the start of each interview. All participants were introduced to the purpose of the study. No financial incentives were offered or transacted. The confidentiality and anonymity of the data were ensured according to national standards.